Get a Roundup of Psychedelic News Stories in Your Inbox.

[contact-form-7 id="44" title="Newsletter Subscription Form"]

By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.

Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy TrialShutterstock.com

Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy Trial

Chief Medical Officer Dr. Guy Goodwin clarifies "COMP360 psilocybin therapy was generally well-tolerated" by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.
Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.
PharmaTher Believes Ketamine Could Treat This Rare Neurological ConditionShutterstock.com

PharmaTher Believes Ketamine Could Treat This Rare Neurological Condition

,
The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.
Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy TrialShutterstock.com

Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy Trial

Chief Medical Officer Dr. Guy Goodwin clarifies "COMP360 psilocybin therapy was generally well-tolerated" by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.
Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.
PharmaTher Believes Ketamine Could Treat This Rare Neurological ConditionShutterstock.com

PharmaTher Believes Ketamine Could Treat This Rare Neurological Condition

,
The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.
How the COVID Pandemic Inspired Wakeful Travel's Psychedelic Integration Journals

How the COVID Pandemic Inspired Wakeful Travel’s Psychedelic Integration Journals

A travel journal company pivots from external trips to those unfolding in the mind, and the psychedelic community is embracing the one-of-a-kind integration workbook with open arms.
Psychedelic Business Spotlight: November 19

Psychedelic Business Spotlight: November 19

This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.

Psychedelic Business Spotlight: November 12

This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly ReduceShutterstock.com

Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce

,
“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David J. Hellerstein, who was evaluating Compass Pathways' novel drug formulation COMP360.
Cybin’s Novel Analog Shows Multiple Advantages Over Oral Psilocybin

Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’

Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.
Psychedelic Business Spotlight: November 5

Psychedelic Business Spotlight: November 5

This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
Why We're Excited About Compass Pathways New Clinical Trial Treating PTSD With PsilocybinShutterstock.com

Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin

,
Compass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial, using psilocybin (the active ingredient in magic mushrooms) to treat PTSD, and there are multiple reasons to be excited about it. The Phase-2…
Shutterstock.com

FDA Approves First Clinical Trial Using Naturally Sourced Psychedelics

This trial, using Filament Health's botanical drug candidates, is the first to assess the direct administration of psilocin.
TRIPP Wants You to 'Be Here Now,' With or Without Ram DassLove Serve Remember Foundation / TRIPP

TRIPP Wants You to ‘Be Here Now,’ With or Without Ram Dass

Psychedelic Spotlight trips with Ram Dass at the 50th anniversary celebration of the spiritual teacher's iconic book.
Could the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

"Something that people used to speak about only in whispers is now standard policy," says the psychedelics researcher, with 20 years of experience, in a wide-ranging Q&A.

Psychedelic Business Spotlight: October 29

This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
Psychedelic Business Spotlight: October 22

Psychedelic Business Spotlight: October 22

This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.

Psychedelic Business Spotlight: October 15

This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.
Why Psychedelic Stocks Have Crashed in the Last 3 Months

Why Psychedelic Stocks Have Crashed in the Last 3 Months

Our resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.
You Can Now Buy Marley One Functional Mushrooms on Amazon

You Can Now Buy Marley One Functional Mushrooms on Amazon

Silo Wellness CEO Douglas K. Gordon tells Psychedelic Spotlight that this is a "crucial" step toward "the mainstream acceptance of psychedelics and overall de-stigmatization of mushrooms, by way of the functional category."
Psychedelic Business Spotlight: October 8, 2021

Psychedelic Business Spotlight: October 8, 2021

This week in psychedelic business news: Enveric Biosciences uses AI to identify viable psychedelic drug candidates; Novamind launches end-of-life palliative care program; and PharmaTher tests ketamine to treat Parkinson's Disease.
Psychedelic Business Spotlight: October 1, 2021

Psychedelic Business Spotlight: October 1, 2021

This week in psychedelic business news: more evidence supporting ketamine for depression; a new use for MDMA; Lobe Sciences makes a leap in treating PTSD; Delix raises big bucks; and BetterLife Pharma patents solution for cluster headaches.
Why NeonMind Is Betting on Psilocybin to Curb the Global Obesity Epidemic

Why NeonMind Is Betting on Psilocybin to Curb the Global Obesity Epidemic

The psychedelic bioscience company's top advisor tells Psychedelic Spotlight that psilocybin "affects at least the 5h2C receptor, which is dedicated towards appetite and appetite suppression."
Mind Cure Health Targeting Hypoactive Sexual Desire Disorder with MDMA

Mind Cure Health Targeting Hypoactive Sexual Desire Disorder with MDMA

“Women’s desire issues have not been adequately addressed to date, and we believe this treatment incorporating MDMA and psychotherapy has real promise," says CEO Kelsey Ramsden
How Cybin Is 'Revolutionizing' Mental Healthcare with Novel Psychedelic Compounds

How Cybin Is ‘Revolutionizing’ Mental Healthcare with Novel Psychedelic Compounds

CEO Doug Drysdale explains several key factors in making psychedelic-assisted therapy accessible for the millions of people suffering around the globe.
Psychedelic Business Spotlight: September 24, 2021

Psychedelic Business Spotlight: September 24, 2021

This week in psychedelic business news: two patents may revolutionize the medical application of psychedelic compounds; DMT and ibogaine clinical trials show promise; and stock news for psychedelic investors.
Here's How Many Billions of Dollars the Global Psychedelic Market May Be Worth by 2026

Here’s How Many Billions of Dollars the Global Psychedelic Market May Be Worth by 2026

Recent analysis cites positive results of clinical psychedelic trials, coupled with a large amount of capital investment into biotech companies.
Psychedelic Business Spotlight: September 17, 2021

Psychedelic Business Spotlight: September 17, 2021

This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.
United States' First Actively Managed Psychedelics ETF Launches on NYSE Arca

United States’ First Actively Managed Psychedelics ETF Launches on NYSE Arca

PSIL is the third psychedelics ETF to hit the markets after the launch of the world’s first psychedelic ETF earlier this year.
Hallucinogen Persisting Perception Disorder Is a Psychedelics Problem Ehave Wants to Solve

Hallucinogen Persisting Perception Disorder Is a Psychedelics Problem Ehave Wants to Solve

"HPPD is a discomfort. Some people have it for 10, 15, 20 years and they regret the day they did the drug that caused it," says the CEO of Ehave.
Psychedelic Business Spotlight: Big Week for Research and Clinical Trials

Psychedelic Business Spotlight: September 10, 2021

This week in psychedelic business news: major DMT development for stroke treatment; a propriety psilocybin formulation has potential to treat obesity; two more companies join the OTC Pink Market.
Psychedelic Business Spotlight: September 3, 2021

Psychedelic Business Spotlight: September 3, 2021

"Magic Truffle" producer and distributor Red Light Holland has had a very busy week, and Filament Health files a "milestone" patent.
Psychedelic Sector Reaches International Supply Chain Milestones

Psychedelic Sector Reaches International Supply Chain Milestones

Canadian psychedelics production company Red Light Holland announces largest legal sale and import of psilocybe truffles.
Mindset Pharma's DMT-Inspired Drug Candidates Could Address Serotonin Syndrome Challenge

Mindset Pharma’s DMT-Inspired Drug Candidates Could Address Serotonin Syndrome Challenge

,
“The data suggests that we have a new drug that may be at least as effective, if not more effective, than 5-MeO-DMT and, more importantly, it looks like it is much safer," says Mindset Pharma CEO James Lanthier.
I Drank a 'Mushroom Latte' Every Morning for Two Weeks: Here's How I Felt

I Drank a ‘Mushroom Latte’ Every Morning for Two Weeks: Here’s How I Felt

Everyday Dose is a tasty coffee replacement, which is easy to make and loaded with healthy benefits.
Psychedelic Business Spotlight: August 27, 2021

Psychedelic Business Spotlight: August 27, 2021

Delic establishes medical board to oversee psychedelic treatment protocols, cool new delivery systems investigated for psychedelics, and VR meets psychedelic therapies, finally. 
MindSet Pharma Says Its Proprietary Psilocybin Formula Is the 'Perfect Microdosing Drug'

MindSet Pharma Says Its Proprietary Psilocybin Formula Is the ‘Perfect Microdosing Drug’

"The potential market for microdosing could be absolutely enormous because it is easier, more convenient, and more familiar," says Mindset Pharma CEO James Lanthier.
MindMed, Forian Developing Personalized Psychiatry for Anxiety Disorders

MindMed, Forian Developing Personalized Psychiatry for Anxiety Disorders

MindMed is currently conducting several clinical trials using psychedelic-inspired medicines, including studying LSD experiential therapy for anxiety, LSD microdosing for adult ADHD, and 18-MC for opioid withdrawal.
TRIPP Acquires PsyAssist to Empower Psychedelic Therapies with Virtual Reality

TRIPP Acquires PsyAssist to Empower Psychedelic Therapies with Virtual Reality

Clinicians are currently using TRIPP to help immerse patients into alternative realities and to support patients’ wellbeing before, during, and after ketamine-assisted therapy.

Psychedelic Business Spotlight: August 20, 2021

This week in psychedelic business news: More psychedelic clinical trials are green-lighted, new partnerships inked, and Beckley Psytech successfully completes upsized Series B financing. 
Why PsyBio Is Using Biosynthetic Psilocybin, Not Magic Mushrooms, to Build Better Therapeutics

Why PsyBio Is Using Biosynthetic Psilocybin, Not Mushrooms, to Build Better Therapeutics

"A mushroom is not a pharmaceutical product," CEO Evan Levine stresses, and explains why his company's method of biologically engineering psilocybin is "cheaper, faster, greener."
Beckley Psytech Raises $80 Million to Fund Psychedelic Research Pipeline

Beckley Psytech Raises $80 Million to Fund Psychedelic Research Pipeline

,
The company will use proceeds of the fundraising round to complete its ongoing Phase 1B trial on low-dose psilocybin in patients suffering from a rare headache condition with no approved medications to treat it.
How Ayahuasca and Volcanic Disaster Pulled Microdosing Mentor Laura Dawn Out of the 'Psychedelic Closet'

How Ayahuasca and Volcanic Disaster Pulled Microdosing Mentor Laura Dawn Out of the ‘Psychedelic Closet’

,
The Psychedelic Spotlight podcast guest also addresses criticism that she is a white woman working with sacred plant medicine, and how that inspired her next non-profit venture.
Psychedelic Business Spotlight: August 13, 2021

Psychedelic Business Spotlight: August 13, 2021

This week in psychedelic business news: Psychedelics in development to treat eye diseases and stroke; companies gear up for new clinical trials investigating psychedelics for general anxiety, chronic pain, and eating disorders.
Nova Mentis Reaches Milestone Developing Psilocybin to Treat Autism

Nova Mentis Reaches Milestone Developing Psilocybin to Treat Autism

,
Nova Mentis says that psilocybin could be a novel, first-in-class treatment for a brain disorder that leads to learning disabilities and behavioral problems.
Wesana Health Launches Animal Studies for Psilocybin and TBI

Wesana Health Launches Animal Studies for Psilocybin and TBI

,
According to the CDC, about 166 Americans die from TBI-related conditions each day.
Filament Health Patents Natural Extraction Technique for Superior, Cheaper Psilocybin

Filament Health Patents Extraction Technique for Superior, Cheaper Natural Psilocybin

The Vancouver-based company says it has overcome the challenges of natural extraction with its new technology, which can produce superior psilocybin at a lower cost.
Psychedelic Business Spotlight: August 6, 2021

Psychedelic Business Spotlight: August 6, 2021

Another clinic gets approval to conduct MDMA research, and new psychedelic research facilities open in Australia and the U.S., plus two game-changing psilocybin patents.

Why Dimensions Health Centers Founders Embrace Plant Medicine Ceremonies Over Clinical Treatment

CEO Christopher Dawson and COO Andrew Galloway spent years working in clinical mental health treatment centers before betting big on psychedelics and ancient healing methods.
FDA Green Lights Ketamine for Treatment of ALS

FDA Green Lights Ketamine for Treatment of ALS

,
"This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine," says PharmaTher CEO Fabio Chianelli.

Mindset Pharma Files Patent for Quickest, Cheapest Method to Synthesize Psilocybin

"Based on our research, we think we're able to get to psilocybin in fewer steps than any of the other published methods," says the company's CEO.
Psychedelic Spotlight Business Round Up July 30

Psychedelic Business Spotlight: July 30, 2021

This week in psychedelic business news: More psychedelic-assisted therapy clinics, recruitment begins in early DMT trial, and Filament gets more Health Canada love.
Psychedelic Companies HAVN Life Sciences, MINDCURE Health Reach Manufacturing Milestones

Psychedelic Companies HAVN Life Sciences, MINDCURE Health Reach Manufacturing Milestones

The global supply chain of regulated psilocybin and ibogaine continues to grow as these Canadian companies beef up manufacturing efforts.
Akome Biotech Patents Psychedelic Drug Formulation to Treat Parkinson's Disease

Akome Biotech Patents Psychedelic Drug Formulation to Treat Parkinson’s Disease

,
There is currently no known cure for the disease affecting 10 million people worldwide, but this psychedelics company thinks it has found a "viable candidate" using DMT.
Psychedelic Business Spotlight: July 23, 2021

Psychedelic Business Spotlight: July 23, 2021

This week in psychedelic business news: Psychedelics as a treatment for obesity and TBIs, plus another psychedelic company inches toward listing on NYSE American stock exchange.
Cybin Receives Conditional Approval to Trade on NYSE American

Cybin Receives Conditional Approval to Trade on NYSE American

And in other psychedelic stock news, Origin Therapeutics launches to make equity investments in emerging psychedelics-related companies.
Wake Network Developing Genetics-Based Screening System to Offer Patients Personalized Psychedelic Therapies

Wake Network Partners with Lieber Institute to Develop Genetics-Based Screening System for Psychedelic Therapies

, ,
Fungi bioscience company describes the project as “one of the most robust genetics research initiatives in the emerging psychedelics space to date."
Levitee Labs joins Canadian Securities Exchange CSE

Levitee Labs to Begin Trading on the CSE This Week

The emerging wellness company aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.
'PSY' Becomes First U.S.-Listed Psychedelic ETF

Third Psychedelic Stock ETF Coming Soon, Core One Labs Prepares to List on NASDAQ

Advisorshares Plant Medicine ETF will be listed on the NYSE Arca under the symbol PSIL.
Psychedelic Business Spotlight, July 16

Psychedelic Business Spotlight: July 16, 2021

This week in psychedelic business news: A generous donation to advance MDMA research, psilocybin for end-of-life anxiety, and provisional patents filed for synthesizing ibogaine.

Global Trac Solutions Expands Investment in Psychedelic App PsycheDev and You Can Test It Out

The PsycheDev app guides users through intention setting, meditation, learning, contemplation and questioning, serving as a virtual facilitator and integration coach.
Psychedelics Companies PsyBio Therapeutics and Silo Wellness Start Trading on the OTCQB Venture Market

Psychedelics Companies PsyBio Therapeutics and Silo Wellness Start Trading on the OTCQB Venture Market

The OTCQB is a middle-tier market for entrepreneurial and development stage American and international companies.
Awakn Life Science CEO Anthony Tennyson "Groundbreaking" MDMA discovery

Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat Addiction

, ,
Anthony Tennyson tells the Psychedelic Spotlight Podcast that his company has "discovered receptor sites that MDMA interacts with that we believe nobody else in the world knows about."
Wesana Health to Acquire Psytech

Wesana Health to Acquire Psychedelic Therapy and Software Company PsyTech

, ,
The deal creates Wesana Clinics, a chain of mental health facilities focused on delivering psychedelic-assisted psychiatric care, as well as data platform Wesana Solutions.
Psychedelic Business Spotlight

Psychedelic Business Spotlight: July 9, 2021

This week in psychedelic business news: It’s all about partnerships and acquisitions designed to advance psychedelic therapies for depression, suicidal ideation, pain, and more.
Psilocybin depression treatment

Psychedelic Biotech Company Cybin Partners with Greenbrook to Develop Innovative Depression Treatment

, ,
Cybin CEO says agreement "serves as a major step toward establishing a national distribution network for future psychedelic therapies."
Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology

Numinus Wellness to Acquire Neurology Centre of Toronto to Create Psychedelic Treatment Facility

,
NCT will utilize Numinus' expertise in psychedelic-assisted therapy to create a specialization in the application of psychedelics in the field of neurology
Psychedelic Business Spotlight

Psychedelic Business Spotlight: July 2, 2021

This week in psychedelic business news: Companies embrace the psychedelic aspects of VR, Braxia trains therapists in psychedelic best practices, and Allied gears up to provide its psychedelic formulation to PTSD patients.
Psychedelics and Depression

Havn Life to Cultivate Psilocybin in Jamaica through Hypha Wellness Partnership

Havn Life Sciences is expanding its psilocybin cultivation in Jamaica where the psychedelic mushrooms are legal to grow.

Psychedelic Business Spotlight: June 25, 2021

This week in psychedelic business news: A next-gen psychedelic for stroke care, a major merger, and two more companies list on NEO Exchange.
Former Director of Psychiatric Products at FDA Joins Psychedelic Life Sciences Company Cybin

Former Director of Psychiatric Products at FDA Joins Psychedelic Life Sciences Company Cybin

Former Food and Drug Administration division director Dr. Thomas Laughren has joined the psychedelic life sciences team at Cybin.
Silo Wellness Launches 'Marley One' Brand of Functional and Psychedelic Mushrooms

Silo Wellness Launches ‘Marley One’ Brand of Functional and Psychedelic Mushrooms

The Bob Marley-inspired line of psychedelic and functional mushrooms, Marley One, has officially launched through partner Silo Wellness.
Atai Life Sciences Valued At More Than $3 Billion After IPO

Atai Life Sciences Valued At More Than $3 Billion After IPO

German psychedelic pharmaceutical company Atai Life Sciences is valued at more than $3 billion after its IPO listing on the Nasdaq.
Publicly-Traded Psychedelic Stocks

27 Publicly-Traded Psychedelic Stocks Investors Have Their Eyes On

These psychedelic stocks are all publicly trading. Take a look at the companies leading the psychedelic medicine revolution.
Psychedelic Business Spotlight: June 18, 2021

Psychedelic Business Spotlight: June 18, 2021

This week in psychedelic business news: Patent progress for biosynthetic psilocybin, psychedelics for brain health, and psychedelic and cannabis companies team up in the name of research.
Peter Thiel-Backed Atai Life Sciences Announces IPO With $2 Billion Valuation

Peter Thiel-Backed Atai Life Sciences Announces IPO With $2 Billion Valuation

Atai Life Sciences is the latest psychedelic company to announce plans to IPO. The Peter Thiel-backed biotech startup is valued at more than $2 billion.
Psychedelic Business Spotlight: June 11, 2021

Psychedelic Business Spotlight: June 11, 2021

This week in psychedelic business news: An all-female biotech company, psychedelic-assisted psychotherapy for COVID front-liners, and more.
Field Trip Health Trades on TSE

Field Trip Health Begins Trading on TSE, Sets Sights on Nasdaq

Psychedelic lifestyle brand Field Trip Health is now trading on the Toronto Stock Exchange under the symbol "FTRP".
GH Research Is Taking its Psychedelic 5-MeO-DMT 'Toad Venom' Public

GH Research Is Taking Psychedelic 5-MeO-DMT ‘Toad Venom’ Public

GH Research is taking its psychedelic 5-MeO-DMT public on the Nasdaq with an IPO valued at more than $100 million.
AI Tech-Led Psychedelic Therapy Platform Nue Life Health Raises $3.3 Million

AI Tech-Led Psychedelic Therapy Platform Nue Life Health Raises $3.3 Million

Nue Life Health is a new therapy platform relying on AI and music as well as psychedelics for customized healing.
Psychedelic Business News Spotlight

Psychedelic Business Spotlight: June 4, 2021

This week in psychedelic business: Mindset Pharma's new research, synthetic ibogaine, and the Western Hemisphere gets its first “smart shop.”
'PSY' Becomes First U.S.-Listed Psychedelic ETF

‘PSY’ Becomes First U.S.-Listed Psychedelic ETF

Defiance Next Gen Altered Experience ETF began trading Friday on the New York Stock Exchange under the symbol PSY.
Psychedelic Business Spotlight: May 8, 2021

Psychedelic Business Spotlight: May 28, 2021

This week in psychedelic business news: NeonMind's Medical Advisory Board, Mynd's public listing, and a new study supports novel use of DMT.
Psychedelic Platform Field Trip Health Gets Uplisting Conditional Approval for Toronto Stock Exchange

Psychedelic Platform Field Trip Health Gets Uplisting Conditional Approval for Toronto Stock Exchange

Psychedelic healing platform Field Trip Health has received conditional approval to uplist to the Toronto Stock Exchange.
Psychedelic Drug Development Company Mynd Life Sciences Goes Public on the CSE

Psychedelic Drug Development Company Mynd Life Sciences Goes Public on the CSE

Psychedelic drug development company Mynd Life Sciences has gone public on the CSE.
Enveric Biosciences Acquires Psychedelic Drug Discovery Platform MagicMed Industries

Enveric Biosciences Acquires Psychedelic Drug Discovery Platform MagicMed Industries

Cannabis-focused Enveric Biosciences will acquire Canadian psychedelic drug discovery platform MagicMed Industries.
Psychedelic Business Spotlight: May 21, 2021

Psychedelic Business Spotlight: May 21, 2021

This week in psychedelic business news: Therapists cleared to try MDMA, alternative medicine guru promotes psychedelic therapy, and the Swiss green-light new mescaline study. On the heels of the recently released trial data showing how MDMA-assisted…
Shark Tank’s Kevin O’Leary Deep Dives Into Psychedelics

Shark Tank’s Kevin O’Leary Deep Dives Into Psychedelics

Shark Tank investor Kevin O'Leary is a big fan of psychedelics. Here's everything you need to know.
How to Become a Psychedelic Facilitator

PharmaDrug Launches E-Store Positioned for U.S. Psychedelic Sales

PharmaDrug is bringing an online shop to the U.S. for sales of functional mushrooms and psychedelics once legal.
Business Spotlight

Psychedelic Business News Spotlight: May 14, 2021

This week in psychedelic business news: Therapeutic uses of salvinorin A, a 5-MeO-DMT retreat, and World Boxing Council explores psychedelics.
Daniel Carcillo's Wesana Health Goes Public on CSE

Daniel Carcillo’s Psychedelic Life Sciences Company Wesana Health Goes Public on CSE

Daniel Carcillo's psychedelic life sciences company is now trading on the Canadian Securities Exchange.
DMT-Focused Psychedelic Company Small Pharma Launches on TSX Venture Exchange

DMT-Focused Psychedelic Company Small Pharma Launches on TSX Venture Exchange

DMT-focused psychedelic therapy company Small Pharma is listing on the Canadian TSK Venture Exchange as it ramps up its offerings.
Psychedelic Investment Platform Clarify Pharma to Go Public With £10.5 Million Valuation

Psychedelic Investment Platform Clarify Pharma to Go Public With £10.5 Million Valuation

The psychedelic investment platform Clarify Pharma is expecting to go public on the AQSE with a valuation of £10.5 million.
Mike Tyson Invests In Psychedelic Wellness Company Wesana Health

Mike Tyson Invests In Psychedelic Wellness Company Wesana Health

,
Former heavyweight boxing champion Mike Tyson announced he's an investor in psychedelic wellness company Wesana Health.
Psychedelic Business News Spotlight: May 7, 2021

Psychedelic Business News Spotlight: May 7, 2021

This week in psychedelic business news: LSD for pain, DMT and organ transplants, Champignon Brands is now Braxia Scientific Corp, and more.

Canada Approves New Leaf’s Bid to Build First-Of-Its-Kind Psilocybin Lab

New Leaf Canada has received permission from Health Canada to build a first-of-its-kind laboratory to produce and study psilocybin and psilocin.
Psychedelic Companies Combine Forces to Create Virtual Reality Experience

Psychedelic Companies Combine Forces to Create Virtual Reality Experience

A new psychedelic VR experience is coming thanks to a partnership between Lobe Sciences and Virtual Psychedelics.
Psychedelic Business News Spotlight: April 30, 2021

Psychedelic Business News Spotlight: April 30, 2021

This week in psychedelic business news: Cybin’s experimental psychedelic takes aim at alcohol use disorder, Numinus seeks volunteers for its natural psilocybin extract, and another psychedelic company trades on Nasdaq.  Toronto-based…
Kevin O'Leary-Backed MindMed Is 2nd Psychedelic Company to List On Nasdaq

Kevin O’Leary-Backed MindMed Will Be 2nd Psychedelic Company to List On Nasdaq

MindMed will take its Kevin O'Leary-backed platform onto the Nasdaq Tuesday as only the 2nd psychedelic company to do so.
Psychedelic Business News Spotlight: April 23, 2021

Psychedelic Business News Spotlight: April 23, 2021

This week in psychedelic business news: Atai to raise $100 million, Silo's psilocybin nasal spray, and more.
Psychedelic Start-Up Atai Life Sciences to Raise $100 Million in IPO, 2nd to List on Nasdaq

Psychedelic Start-Up Atai Life Sciences to Raise $100 Million in IPO, 2nd to List on Nasdaq

Atai Life Sciences is now the second psychedelic company to list on Nasdaq, with plans to raise $100 million for its IPO.
Psychedelic Business News Spotlight: April 16, 2021

Psychedelic Business News Spotlight: April 16, 2021

This week in psychedelic business news:psilocybin’s genome sequencing explored, psychedelics meet artificial intelligence, and more.
GH Research Raises $125 Million to Fund DMT Treatment for Depression

GH Research Raises $125 Million to Fund DMT Treatment for Depression

GH Research closed a $125 million Series B financing round to fund the advancement of its 5-MeO-DMT treatment.
psychedelic mushrooms

Silo Wellness Expands Shareholder Base to Europe

Toronto's Silo Wellness is now trading on the German Stock Exchange as demand for psychedelic treatments expands.

Daniel Carcillo’s Psychedelic Startup Wesana Health Raises More Funds, On Track to Go Public

,
Former NHL player Daniel Carcillo's psychedelic startup Wesana Health is preparing to take the company public.
Psychedelic Business News Spotlight: April 9, 2021

Psychedelic Business News Spotlight: April 9, 2021

This week in psychedelic business news: a psilocybin delivery system for brain inflammation, a genetic test to predict your psychedelic-assisted therapy experience, and a potential first treatment for a debilitating form of schizophrenia.
Mydecine Prepares to Present Four Novel Psychedelic Candidates

Mydecine Prepares to Present Four Novel Psychedelic Candidates

,
Colorado-based Mydecine is launching four new psychedelic candidates for use in treating conditions like anxiety and depression.
Psychedelic Business News Spotlight: April 2, 2021

Psychedelic Business News Spotlight: April 2, 2021

This week in psychedelic business news: cannabis dives in, ketamine delivery, and psilocybin for autism anxiety.
How Field Trip Health Is Leading the Psychedelic Market Boom

How Field Trip Health Is Leading the Psychedelic Market Boom

Field Trip Health is brining psychedelics to the forefront of mental health wellness.
Psychedelic Business News Spotlight: March 26, 2021

Psychedelic Business News Spotlight: March 26, 2021

This week in psychedelic business news sees pharmaceutical giant Merck enter the arena, psilocybin research, and more.
Psychedelic Business News Spotlight: March 18, 2021

Psychedelic Business News Spotlight: March 19, 2021

This week in psychedelic business news, quick dissolve LSD, novel psychedelic molecules move into investigational studies, and more.
These 24 Psychedelic Patents Are Paving the Way for Medicine 2.0

These 24 Psychedelic Patents Are Paving the Way for Medicine 2.0

,
Patents of psychedelic substances are paving the way for new research and treatment options for a variety of diseases.
How The Conscious Fund Is Changing Perceptions About Psychedelics

How The Conscious Fund Is Changing Perceptions About Psychedelics

UK venture capital fund The Conscious Fund is working to make psychedelics more accessible and functional in various capacities.
Psychedelic Business News Spotlight: March 12, 2021

Psychedelic Business News Spotlight: March 12, 2021

This week in psychedelic business news, Canada expands legal distribution for psychedelics, therapeutic DMT stroke treatment, and more.
Canada Expands Psychedelic Approvals for Numinus

Canada Expands Psychedelic Approvals for Numinus

Numinus Biosciences has received expanded regulatory approval in Canada for psychedelic use and distribution.
North America Is Poised to Take the Lead In Emerging Psychedelic Drug Market

North America Is Poised to Take the Lead In Emerging Psychedelic Drugs Market

,
The psychedelic drugs market is finding a strong base in North America, according to new data. The U.S. and Canada in particular are supporting its expansion.
New App Creates Psychedelic Experience Without the Need for Substances

Can An App Give You a Psychedelic Experience Without Taking Drugs? Lumenate Says Yes

,
Lumenate is an app that simulates a psychedelic experience without the need for illegal substances.
Defiance Just Launched the World's Second Psychedelic-Focused ETF

Defiance Just Launched the World’s Second Psychedelics-Focused ETF

Defiance has launched the world's second psychedelics-focused ETF as investing in psychedelic therapy and treatment accelerates.
Psychedelic Business News Spotlight: March 5, 2021

Psychedelic Business News Spotlight: March 5, 2021

This week in psychedelic business news: two companies enter the Canadian Stock Exchange, AI comes to psychedelic treatment, and psilocybin comes to Brazil.
Psychedelic Biotech Company Atai Life Sciences Valued At $2 Billion

Psychedelic Biotech Company Atai Life Sciences Valued At $2 Billion

Biotech company Atai Life Sciences has earned a $2 billion valuation for its work in developing psychedelic treatments for mental health issues.
Psychedelic Business News Spotlight: February 26, 2021

Psychedelic Business News Spotlight: February 26, 2021

This week in psychedelic business news, Field Trip upsizes its bought deal, psilocybin truffles head to Brazil, another company goes public, and more.
First Of Its Kind $10 Million Psychedelic Research Center Comes to NYU

‘One-of-a-Kind’ $10 Million Psychedelic Research Center Comes to NYU

,
NYU will open a $10 million psychedelic research center to further its work in using psychedelic substances to treat mental health issues.
Psychedelic Business News Spotlight: February 19, 2021

Psychedelic Business News Spotlight: February 19, 2021

This week in psychedelic business news: MindMed acquires a digital health company, Mindest Pharma goes public, new MDMA treatment for PTSD, and more.
Psychedelic Spotlight Business News

Psychedelic Business News Spotlight: February 12, 2021

This week in Psychedelic business news: MindMed has a new partner, Mydecine closes a funding round, and the world’s first legal psilocybin cultivation facility launches.
Psychedelic Business Spotlight: February 5, 2021

Psychedelic Business News Spotlight: February 5, 2021

This week in psychedelic business news, Super Mario's magic mushroom gets a new use, Mindset files three patents, Bright Minds goes public, and more.
5meo-dmt

5-MeO-DMT: Can ‘Toad Juice’ Cure Depression?

, ,
Clinical trials will look at the benefits of 5-MEO DMT as a treatment for relief from a number of mental health issues including depression.
psyk etf

The World’s First Psychedelic ETF Just Launched: Here’s Why That Matters

The Horizons Psychedelic ETF launched on the Canadian NEO stock exchange last month. Here's what that means for the industry, and the future.
psilocybin truffles

How Red Light Holland Is Bringing Psilocybin Truffles Mainstream

,
Canada's Red Light Holland is preparing to take its psilocybin truffles global as demand for psychedelics heats up.
neon mind

Psychedelic Business News Spotlight: January 29, 2021

This week in psychedelic business news, Psyence Group's psilocybin harvest, NeonMind's new CEO, and Mydecine sponsors new research.
Psychedelic Business News Spotlight: January 22, 2021

Psychedelic Business News Spotlight: January 22, 2021

This week in psychedelic industry news: the first psychedelic stock index, new products, mergers, and funds.

Daniel Carcillo’s Wesana Health Raises $4 Million to Expand Psychedelic Research

,
Wesana Health, founded by former NHL star Daniel Carcillo, has raised $4 million to continue its psychedelic research for traumatic brain injuries.
Psychedelic Business News Spotlight: January 15, 2021

Psychedelic Business News Spotlight: January 15, 2021

This week in psychedelic business news, IPOs, employee stock options, mergers, research, and more.
Psychedelic Business News

Psychedelic Business News Spotlight: January 08, 2021

This week in psychedelic business news, Mydecine, Neon Mind, Ehave, and more.
NeonMind Takes Psilocybin Therapy Public

NeonMind Takes Psilocybin Therapy Public

NeonMind is the latest psychedelic company to go public. It's the first to launch on the Canadian Stock Exchange in 2021.
5 Psychedelic Apps

These 5 Apps Are Made for Taking Psychedelics

,
Taking psychedelics? There's an app for that. These companies are leading the way with trip guides, support, and more.
Psychedelic Trend Predictions 2021

7 Psychedelic Trend Predictions for 2021

The momentum for psychedelics is snowballing, and 2021 is expected to be an even bigger and better year for the industry.
Queen’s University Launches Psychedelic Research Collaborative

Psychedelic Business News Spotlight: December 17, 2020

The UK gets its first psychedelic VC fund, psychedelic treatment for Parkinson's, and more business news.

Psychedelic Business News Spotlight: December 10, 2020

This week in psychedelic business news: Motley Fool bets on MindMed, mushrooms go from Jamaica to Canada, and more.
Singapore Begins Administering Ketamine-Type Therapy for Depression

Psychedelic Life Science Company Cybin Acquires Ketamine Drug Maker Adelia Therapeutics

Cybin Inc., has acquired the ketamine drug Spravato manufacturer Adelia Therapeutics in its first major acquisition.
Psychedelic Business News Spotlight

Psychedelic Business News Spotlight: December 3, 2020

This week in psychedelic business news: Numimus Wellness Inc. annouces a major partnership, Field Trip expands its investor relations, serial entrepreneur Peter Thiel invests in psychedelics for mental health treatment, and more. Numimus…
Peter Thiel Invests $12 Million In Psychedelic Drug Manufacturer

Peter Thiel Invests $12 Million In Psychedelic Drug Manufacturer

Billionaire tech investor Peter Thiel is the latest to join the booming psychedelic industry. The PayPal co-founder backed Berlin’s ATAI Life Sciences in a $125 million series C funding round. Thiel’s investment firm, Thiel Capital,…
Psychedelic Tech Company Cybin Brings In a $45 Million

Psychedelic Tech Company Cybin Brings In a $45 Million (CAD) Funding Round

Canadian pharmaceutical therapies company Cybin announced $45 million (CAD) in gross proceeds on a private placement of 60,000,000 subscription receipts as part of a new funding round. The company will use the funds to further expand its development…
Dr. Andrew Weil Joins Advisory Board for Psychedelic Therapy Platform

Dr. Andrew Weil Joins Advisory Board for Psychedelic Therapy Platform Field Trip

Acclaimed integrative medicine pioneer, Dr. Andrew Weil, has joined the advisory board for psychedelic therapy platform Field Trip Health. “I am extremely pleased to be joining the medical advisory board at Field Trip,” Dr. Weil…
Field Trip Is the Latest Psychedelic Therapy Company to Go Public

Field Trip Is the Latest Psychedelic Therapy Company to Go Public

Another psychedelic therapy-based company has gone public. Toronto-based Field Trip Health Ltd., which operates the mobile therapy app Trip, is now trading on the Canadian Securities Exchange under the symbol FTRP. Psychedelic therapy for…
Ibogaine and LSD Producer MindMed Applies for Nasdaq Up-Listing

Ibogaine and LSD Producer MindMed Applies for Nasdaq Up-Listing

Just days after UK-based psychedelic developer Compass Pathways went public, New York-based MindMed has applied for a Nasdaq up-listing. The company, valued at $190 million,  is already listed on Canada’s NEO exchange. MindMed…
Compass Pathways IPO Brings $1 Billion Valuation

Compass Pathways IPO Brings $1 Billion Valuation

UK-based Compass Pathways led a groundbreaking IPO last week. Share prices spiked 71 percent to nearly $30 after the initial offering of 7.5 million shares, which launched at $17 each. Current value of the company based on its 34 million shares…
Investors Are Betting On Psychedelics

Why Investors Are Betting On Psychedelics

While they’ve historically brought the risk of long jail sentences, psychedelics are now bringing another long-term scenario: big-time investments. The potential for psychedelics in treating mental disorders such as depression, suicidal…
The Psychedelic Medicine Association

The Psychedelic Medicine Association Launches to Align the Industry

A first of its kind, The Psychedelic Medicine Association (PMA) is set to launch on September 29th. The association aligns medical establishments, patients, and industry leaders in the advancement of psychedelic therapy. “We want physicians…
Quick-Dissolve Strips to Psychedelics

New Partnership Will Bring Quick-Dissolve Strips to Psychedelics

Psychedelic drugs could soon have a standardized, and much faster delivery method with the announcement last month that ATAI Life Sciences AG and IntelGenx have entered into an agreement to develop polymeric film technologies. The…
CEO of Canadian Stock Exchange on Psychedelic Investments

CEO of Canadian Stock Exchange on Psychedelic Investments

Listening to Richard Carleton – the CEO of the Canadian Securities Exchange – talk about future investment opportunities in the psychedelic space, you come away with two thoughts: The differences between cannabis and psychedelics are stark,…
Canadian Manufacturer Licensed to Make Psilocybin

Canadian Manufacturer Licensed to Make Psilocybin

Vancouver-based Mydecine Innovations Group, Inc., has become the first company to earn the license to legally produce and distribute pharmaceutical-grade psilocybin in Canada, the company announced last month. Mydecine, which also has offices…
Low Doses of LSD Make Opioids Obsolete

Could Low Doses of LSD Make Opioids Obsolete?

Better known for its psychedelic properties, Lysergic Acid Diethylamide (LSD) became extremely popular during the counterculture of the 1960’s. But it wasn’t only popular among the free-loving hippies... What most people fail to realize…
Quest For A Market-Friendly Synthetic Psilocybin

The Quest For A Market-Friendly Synthetic Psilocybin Is Decades In The Making

Exactly 65 years ago, R. Gordon Wasson, a vice president of J.P. Morgan & Co., leaned over the desk of the highest ranking official in a remote Mexican Indian village high atop the Mixeteco mountains and whispered, “Will you help me learn…

© 2021 Psychedelic Spotlight. All rights reserved. Owned and operated by Global Trac Solutions, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.